FINNENCE ▪ THE WIRE FILE
THE WIRE · № 93730
SEC Filing■ Mixed
WDC filed 8-K on 2026-10-22
KINDSEC Filing
DIRECTION■ Mixed
SOURCES1
ENTITIES1
STORY SIZESTANDALONE
FIRST SEEN
LAST UPDATE
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
THE MACHINE IS STILL READING THIS ITEM — ANALYSIS LANDS WITHIN MINUTES OF INGESTION.
FULL DISPATCH
WDC (CIK 0000106040) filed a 8-K on 2026-10-22. 8-K items: item 2.02 (results of operations (earnings)) item 9.01.
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
SUBJECTWestern Digital · WDC
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
→INFERENCEfilings generate company commentary
New Phase 3 trial: Cefepime-Zidebactam Versus Ceftazidime-Avibactam With or Without Colistin for Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia — Wockhardt2026-10-21 12:00 UTC
New Phase 3 trial: Cefepime-Zidebactam Versus Ceftazidime-Avibactam With or Without Colistin for Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia — Wockhardt2026-10-21 12:00 UTC
→INFERENCEfilings generate company commentary
New Phase 3 trial: A Study to Learn About Revaccination With a Vaccine Called RSVpreF in Older Adults — Pfizer2026-10-21 12:00 UTC
New Phase 3 trial: A Study to Learn About Revaccination With a Vaccine Called RSVpreF in Older Adults — Pfizer2026-10-21 12:00 UTC
→INFERENCEfilings generate company commentary
New Phase 3 trial: A Trial to Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Standard of Care in Newly Diagnosed Multiple Myeloma — Gilead Sciences2026-10-21 12:00 UTC
New Phase 3 trial: A Trial to Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Standard of Care in Newly Diagnosed Multiple Myeloma — Gilead Sciences2026-10-21 12:00 UTC
→INFERENCEfilings generate company commentary
New Phase 3 trial: Long-Term Safety and Tolerability of Nizubaglustat in Participants With Rare Lysosomal Disorders — Azafaros B.V.2026-10-21 12:00 UTC
New Phase 3 trial: Long-Term Safety and Tolerability of Nizubaglustat in Participants With Rare Lysosomal Disorders — Azafaros B.V.2026-10-21 12:00 UTC
→INFERENCEfilings generate company commentary
New Phase 3 trial: A Study of HS-10382 Versus Investigator-selected TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP — Jiangsu Hansoh Pharmaceutical Co., Ltd.2026-10-21 12:00 UTC
New Phase 3 trial: A Study of HS-10382 Versus Investigator-selected TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP — Jiangsu Hansoh Pharmaceutical Co., Ltd.2026-10-21 12:00 UTC
→INFERENCEfilings generate company commentary
Phase 3 results posted: Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (ARTISTRY-1) — Gilead Sciences2026-10-21 12:00 UTC
Phase 3 results posted: Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (ARTISTRY-1) — Gilead Sciences2026-10-21 12:00 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.